Apurva Kanneganti is a biotechnology investor at Commodore Capital. While completing her medical education, Apurva worked at RAVentures, where she helped identify promising therapeutic targets and build product profiles. She was also an investment fellow at the Cystic Fibrosis Foundation, conducting diligence in early-stage investments in the genetic medicines space.

Apurva earned her MD from Harvard Medical School, where she conducted research across the gene editing and rare disease spaces at Massachusetts General Hospital and the Broad Institute. She graduated with a BA in Chemical and Physical Biology from Harvard College, where she was a John Harvard Scholar and received the Herchel Smith Fellowship for her research examining novel targets in inflammatory bowel disease. She was previously a research fellow at the Harvard Divinity School's Science, Religion, and Culture Colloquium. 

Apurva grew up in Germantown, Tennessee and enjoys reading, writing, and hiking in her free time.